Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, Magenau JM, Schultz K, Tokala H, Ferrara JL, Levine JE, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1407-17. doi: 10.1016/j.bbmt.2014.05.022. Epub 2014 Jun 2.

2.

Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.

Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, Suffredini A, Childs R.

Biol Blood Marrow Transplant. 2005 Jul;11(7):542-50.

3.

Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults.

Omer AK, Kim HT, Yalamarti B, McAfee SL, Dey BR, Ballen KK, Attar E, Chen YB, Spitzer TR.

Am J Hematol. 2014 Jul;89(7):698-705. doi: 10.1002/ajh.23716. Epub 2014 Apr 10.

5.

Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children.

Nishio N, Yagasaki H, Takahashi Y, Hama A, Muramatsu H, Tanaka M, Yoshida N, Yoshimi A, Kudo K, Ito M, Kojima S.

Pediatr Transplant. 2009 Nov;13(7):831-7. doi: 10.1111/j.1399-3046.2008.01068.x. Epub 2008 Nov 1.

PMID:
19067915
6.

Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.

Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2007 Feb;39(4):193-9. Epub 2007 Jan 15.

PMID:
17220905
7.

Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, Storb R.

Biol Blood Marrow Transplant. 2015 Jan;21(1):105-12. doi: 10.1016/j.bbmt.2014.09.021. Epub 2014 Sep 30.

8.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

9.

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Koreth J, Biernacki M, Aldridge J, Kim HT, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Wu CJ, Antin JH, Soiffer RJ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):421-8. doi: 10.1016/j.bbmt.2010.09.013. Epub 2010 Sep 24.

10.

Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.

Cheng GS, Edelman JD, Madtes DK, Martin PJ, Flowers ME.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1169-75. doi: 10.1016/j.bbmt.2014.04.008. Epub 2014 Apr 13.

11.

Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.

Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.

12.

Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.

Schmid I, Stachel D, Pagel P, Albert MH.

Biol Blood Marrow Transplant. 2008 Apr;14(4):438-44. doi: 10.1016/j.bbmt.2008.02.002.

13.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

14.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7.

15.

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.

Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK.

J Clin Oncol. 2005 May 20;23(15):3439-46. Epub 2005 Apr 11.

PMID:
15824415
16.

Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1418-25. doi: 10.1016/j.bbmt.2014.05.021. Epub 2014 Jun 2.

17.

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.

Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Carrabba MG, Bellio L, Milani R, Lorentino F, Stanghellini MT, De Freitas T, Marktel S, Bernardi M, Corti C, Vago L, Bonini C, Ciceri F, Peccatori J.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1506-14. doi: 10.1016/j.bbmt.2015.04.025. Epub 2015 May 19.

18.

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R.

Blood. 2003 Nov 1;102(9):3447-54. Epub 2003 Jul 10.

19.

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier BM.

J Clin Oncol. 2006 Sep 1;24(25):4150-7. Epub 2006 Aug 8.

PMID:
16896000
20.

Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.

Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y.

Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28.

Supplemental Content

Support Center